Efficacy of trimetazidine on functional capacity in symptomatic patients with moderately reduced or left ventricular dysfunction and CAD: a subgroup analysis of the VASCO trial
Dose reduction and contraindication of the novel oral anticoagulant in patients with heart failure and reduced ejection fraction during a follow-up of 27 month. Data from CORONA Trial
A novel oral partial adenosine A1 receptor agonist for the treatment of heart failure: safety and tolerability in healthy volunteers pretreated with beta-blocker